MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges
Clin Pharmacol Ther
.
2020 Apr;107(4):762-772.
doi: 10.1002/cpt.1788.
Epub 2020 Feb 20.
Authors
Sriram Krishnaswami
1
,
Daren Austin
2
,
Oscar Della Pasqua
3
,
Marc R Gastonguay
4
,
Jogarao Gobburu
5
,
Piet H van der Graaf
6
,
Daniele Ouellet
7
,
Stacey Tannenbaum
8
,
Sandra A G Visser
9
Affiliations
1
Pfizer, Groton, Connecticut, USA.
2
GSK, London, UK.
3
University College London, London, UK.
4
Metrum Research Group, Tariffville, Connecticut, USA.
5
University of Maryland, College Park, Maryland, USA.
6
Certara, Canterbury, UK.
7
Pfizer, Collegeville, Pennsylvania, USA.
8
Astellas, Northbrook, Illinois, USA.
9
GSK, Collegeville, Pennsylvania, USA.
PMID:
31955417
PMCID:
PMC7158219
DOI:
10.1002/cpt.1788
No abstract available
MeSH terms
Drug Discovery / standards*
Humans
Models, Biological*